ICHNOS SCIENCES ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD TO INFORM RESEARCH AND DEVELOPMENT STRATEGY IN IMMUNO-ONCOLOGY
Tags:
Immuno-Oncology
Advisory Board
NEW YORK, Feb. 28, 2022 /PRNewswire/ -- Ichnos Sciences Inc., a global biotechnology company developing innovative multispecific antibodies for oncology, today announced the formation of its Scientific Advisory Board (SAB) comprised of experts in oncology, immunology, protein engineering, drug discovery and development. The SAB will provide strategic and scientific counsel to Ichnos Sciences' management and research and development team to help advance the company's proprietary BEAT® platform1 and multispecifics directed at blood cancers and solid tumors.
"The official establishment of our Scientific Advisory Board marks a significant step forward in our path for growth and progress at Ichnos Sciences," said Cyril Konto, M.D., President and C.E.O. of Ichnos Sciences. "We are honored to welcome these leading experts in the fields of protein engineering and immuno-oncology, and I am confident that Ichnos Sciences will benefit from their individual and collective expertise as we work to make cure a reality for cancer patients."
Ichnos Scientific Advisory Board includes:
"Every member of our newly-formed scientific advisory board brings internationally recognized expertise in key areas that will help drive our research and development strategy forward – hematology, oncology, biotechnology, and cancer immunology," said Eric J. Feldman, M.D., Chief Medical Officer of Ichnos Sciences. "As we continue to advance our oncology portfolio, this esteemed board of scientific leaders brings valuable knowledge and experience to Ichnos Sciences. We are excited to partner with them as we work to create new drug options for cancer patients using our BEAT® platform."
About Ichnos Sciences Inc. A fully integrated, global biotech with the spirit of a start-up, Ichnos is shifting the way the world thinks about innovation in medicine through its research and development of transformative, disease-centric treatments in oncology and autoimmune diseases. The company, with headquarters in New York, N.Y., is rapidly advancing a clinical-stage pipeline of novel, first-in-class candidates designed to address complex diseases and to treat patients holistically. With its patented BEAT® technology platform, along with pioneering teams at two locations in Switzerland, Ichnos Sciences has a mission to provide breakthrough, curative therapies that will extend and improve lives, writing a new chapter in healthcare.
1 Bispecific Engagement by Antibodies based on the TCR
CONTACT:Grace MaguireHead of Communications and Corporate AffairsIchnos Sciences[email protected]
SOURCE Ichnos Sciences Inc.
More news releases in similar topics
Cision Distribution 888-776-0942
from 8 AM - 9 PM ET
